Gilead Expands ADC Portfolio; BocoVision Files for Hong Kong IPO for the Third Time
Gilead Sciences
Innovative Drug Developer, Distributor
Tubulis
Developer of Drug Conjugates
DualityBio
Innovative Molecular Type Drug Developer
GSK
Pharmaceutical R&D Manufacturer
Innogen
Biologic Drug Developer for Diabetes and Metabolic Diseases
RinuaGene
mRNA Innovative Drug Developer
Amino Observation - Original Production by the Innovative Drug Team
Author | Huang Kai
Gilead Sciences continues to expand its ADC pipeline.
On December 3, Gilead Sciences announced an exclusive option and license agreement with Tubulis to jointly discover and develop antibody-drug conjugates (ADCs) targeting solid tumors.
GSK Mines Gold in Chinese Molecules.
On December 4, Yingen Bio announced that it had reached an exclusive licensing agreement with GSK for the ADC drug DB-1324. According to the agreement, GSK will obtain the global (excluding mainland China, Hong Kong, and Macao) exclusive rights to DB-1324 to advance the drug's research, development, and commercialization process.
IPO Veteran Tries Again for Listing.
On December 2, according to the HKEX official website, Bokang Shi Yun submitted an IPO application. This is the third time that Bokang Shi Yun has filed with the HKEX in half a year.
In the past day, what are the hot topics in the pharmaceutical markets at home and abroad that are worth paying attention to? Let Amino take you to explore.
/ 01 /
Market Express
1) RinuaGene's DB-1324 Goes Overseas
On December 4, YingBio announced an exclusive licensing agreement with GSK for the ADC drug DB-1324. Under the agreement, GSK will obtain the global (excluding mainland China, Hong Kong, and Macao) exclusive rights to advance the development and commercialization of DB-1324.
/ 02 /
Capital Information
1) Henan Lingrui Pharmaceutical Co.,Ltd. Plans to Acquire 100% Equity of Beijing Jiashitang Biological Medicine Co.,Ltd.
On December 4, Henan Lingrui Pharmaceutical Co., Ltd. announced that the company plans to use its own funds to acquire 100% of the equity of Beijing Jiashitang Biological Medicine Co., Ltd. According to preliminary assessments, the comprehensive valuation of Beijing Jiashitang Biological Medicine Co., Ltd. is temporarily set at no more than RMB 782 million.
2) Yinnuo Pharmaceuticals Submits IPO Application to HKEX
On December 3, according to the Hong Kong Stock Exchange website, Yino Pharmaceuticals filed an IPO application. Yino Pharmaceuticals, established in 2014, is committed to developing innovative therapies for diabetes and other metabolic diseases. The company’s long-acting GLP-1 receptor agonist, Eosupaglutide α, is expected to soon enter the commercialization stage.
3) Bokang Vision Cloud Submits Third Filing to HKEX
On December 2, according to the Hong Kong Stock Exchange website, Prosperity Vision Cloud submitted an IPO application. This marks the third time Prosperity Vision Cloud has filed with the Hong Kong Stock Exchange in the past six months.
/ 03 /
Pharmaceutical News
1) RinuaGene's RG002 Injection Receives Clinical Approval
On December 4, according to the CDE official website, RinuaGene's RG002 injection has been granted clinical approval for the treatment of human papillomavirus (HPV) 16 and/or HPV18-associated grade 2 or 3 cervical intraepithelial neoplasia (CIN2/3).
2) Gaotian Bio HF50 Receives Clinical Approval
On December 4, according to the CDE website, Gaotian Bio's HF50 has been granted clinical approval for the treatment of HER-2 positive or HER-2 low-expression advanced solid tumors.
3) Amgen's AMG 193 Receives Clinical Approval
On December 4, according to the CDE website, Amgen's AMG 193 received clinical approval for the treatment of non-small cell lung cancer with homozygous MTAP deletion.
4) RinuaGene's JS019 Injection Receives Clinical Approval
On December 4, according to the CDE official website, Enrui Ni Biologics' JS019 injection has been granted clinical approval for the treatment of hypereosinophilic syndrome.
5) AstraZeneca's AZD2936 Receives Clinical Approval
On December 4, according to the CDE official website, AstraZeneca's AZD2936 has received clinical approval and is intended for first-line treatment of metastatic non-squamous non-small cell lung cancer.
6) Haisco HSK46575 Tablets Receive Clinical Approval
On December 4, according to the CDE website, Haisco's HSK46575 tablet received clinical approval and is proposed for the treatment of prostate cancer.
7) Innovent Biologics' IBI3009 Receives Clinical Approval
On December 4, according to the CDE official website, IBI3009 from Innovent Biologics was granted clinical approval for the treatment of small cell lung cancer and other neuroendocrine cancers.
8) Kelun Botai's Injectable SKB500 Receives Clinical Approval
On December 4, according to the CDE website, Kelun Botai's injectable SKB500 has been granted clinical approval for the proposed study on treating advanced solid tumors.
9) Yingtac Biotech's IN10018 Tablets Receive Clinical Approval
On December 4, according to the CDE website, Infinity Therapeutics' IN10018 tablet has been granted clinical approval for use in combination with JMKX001899 to treat KRAS G12C mutation-positive locally advanced or metastatic non-small cell lung cancer.
10) Kezhou Drug's HL-085 Capsule Granted Breakthrough Therapy Designation
On December 4, according to the CDE official website, the HL-085 capsule developed by KeyState Pharmaceuticals is proposed to receive a Breakthrough Therapy Designation. The indication is: in combination with vemurafenib for the treatment of adult patients with metastatic colorectal cancer (mCRC) harboring the BRAF V600E mutation who have previously received systemic therapy.
11) Hengrui Medicine's SHR-A2102 for Injection Granted Breakthrough Therapy Designation
On December 4, according to the CDE official website, Hengrui Medicine's SHR-A2102 for injection is proposed to receive Breakthrough Therapy Designation. The indication is: monotherapy for locally advanced or metastatic urothelial carcinoma that has failed previous platinum-based chemotherapy and PD-(L)1 inhibitor treatment.
12) Positive Results from Phase 1b/2a Clinical Trial of Everest Medicines' BTK Inhibitor
On December 4, Everest Medicines announced that the BTK inhibitor EVER001 achieved positive results in the interim data from the Phase 1b/2a clinical trial for the treatment of primary membranous nephropathy (pMN).
13) Bokang Bio freeze-dried intranasal influenza attenuated live vaccine not approved
On December 4, according to the NMPA website, Baike Biotech's freeze-dried intranasal influenza attenuated live vaccine received a drug notification, indicating that it was not approved.
/ 04 /
Instrument Tracking
1) Hongtong Industrial 3D Cardiac Electrophysiology Mapping System Receives Registration Approval
On December 4, according to the NMPA website, Hongtong Industrial's three-dimensional cardiac electrophysiological mapping system obtained registration approval.
2) Coherent Laser Nd:YAG Picosecond Laser Therapy Machine Receives Registration Approval
On December 4, according to the NMPA website, Key Laser's Nd:YAG picosecond laser therapy machine obtained registration approval.
3) Xingjet Bioengineered Bovine Pericardial Heart Valve Receives Registration Approval
On December 4, according to the NMPA website, Xijiete Bioengineered Bovine Pericardial Heart Valve received registration approval.
/ 05 /
Digital Healthcare Daily
1) InferVision's Lung Nodule CT Image Auxiliary Detection Software Receives Registration Approval
On December 4, according to the NMPA website, Infervision Medical's lung nodule CT image auxiliary detection software obtained registration approval.
/ 06 /
Overseas Pharmaceutical News
1) Gilead Sciences Continues to Expand in ADC
On December 3, Gilead Sciences announced that it had signed an exclusive option and license agreement with Tubulis to jointly discover and develop antibody-drug conjugates (ADCs) targeting solid tumors.
PS: Welcome to scan the QR code below to add the WeChat ID of AminoGenius for communication.
